CN110423253A - 一种含单硅烷基的铂配合物及其应用 - Google Patents
一种含单硅烷基的铂配合物及其应用 Download PDFInfo
- Publication number
- CN110423253A CN110423253A CN201910655880.9A CN201910655880A CN110423253A CN 110423253 A CN110423253 A CN 110423253A CN 201910655880 A CN201910655880 A CN 201910655880A CN 110423253 A CN110423253 A CN 110423253A
- Authority
- CN
- China
- Prior art keywords
- platinum complex
- platinum
- containing single
- base containing
- single silane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title claims abstract description 135
- 229910052697 platinum Inorganic materials 0.000 title claims abstract description 72
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 229910000077 silane Inorganic materials 0.000 title claims abstract description 24
- -1 lactyl Chemical group 0.000 claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
- 239000001257 hydrogen Substances 0.000 claims abstract description 8
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 7
- 150000002367 halogens Chemical class 0.000 claims abstract description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 4
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract description 4
- 125000005103 alkyl silyl group Chemical group 0.000 claims abstract description 3
- 125000003368 amide group Chemical group 0.000 claims abstract description 3
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 229940041181 antineoplastic drug Drugs 0.000 claims description 10
- 150000002500 ions Chemical class 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 239000003560 cancer drug Substances 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 14
- 201000011510 cancer Diseases 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 abstract description 10
- 150000003057 platinum Chemical class 0.000 abstract description 9
- 206010059866 Drug resistance Diseases 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 210000005036 nerve Anatomy 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 238000013459 approach Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 238000013518 transcription Methods 0.000 abstract description 3
- 230000035897 transcription Effects 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 238000003756 stirring Methods 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 12
- 239000008367 deionised water Substances 0.000 description 9
- 229910021641 deionized water Inorganic materials 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000004294 195Pt NMR spectroscopy Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000003456 ion exchange resin Substances 0.000 description 5
- 229920003303 ion-exchange polymer Polymers 0.000 description 5
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 5
- 229960001756 oxaliplatin Drugs 0.000 description 5
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 229910001961 silver nitrate Inorganic materials 0.000 description 4
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical class [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 3
- 229940094989 trimethylsilane Drugs 0.000 description 3
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229910000474 mercury oxide Inorganic materials 0.000 description 2
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- KWBXQDNGHQLAMB-UHFFFAOYSA-N 4-sulfanyl-3h-1,3-thiazole-2-thione Chemical compound SC1=CSC(=S)N1 KWBXQDNGHQLAMB-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical group [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910655880.9A CN110423253A (zh) | 2019-07-19 | 2019-07-19 | 一种含单硅烷基的铂配合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910655880.9A CN110423253A (zh) | 2019-07-19 | 2019-07-19 | 一种含单硅烷基的铂配合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110423253A true CN110423253A (zh) | 2019-11-08 |
Family
ID=68411236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910655880.9A Pending CN110423253A (zh) | 2019-07-19 | 2019-07-19 | 一种含单硅烷基的铂配合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110423253A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114195830A (zh) * | 2021-11-30 | 2022-03-18 | 昆明贵研药业有限公司 | 一种顺式-氨-水-铂配合物的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4994591A (en) * | 1989-06-02 | 1991-02-19 | The Research Foundation Of State University Of Ny | Platinum complexes derived from b-silyamines |
JPH0873478A (ja) * | 1994-09-02 | 1996-03-19 | Tanaka Kikinzoku Kogyo Kk | ケイ素を有する抗腫瘍性シクロヘキサンジアミン誘導体白金(iv)錯体 |
-
2019
- 2019-07-19 CN CN201910655880.9A patent/CN110423253A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4994591A (en) * | 1989-06-02 | 1991-02-19 | The Research Foundation Of State University Of Ny | Platinum complexes derived from b-silyamines |
JPH0873478A (ja) * | 1994-09-02 | 1996-03-19 | Tanaka Kikinzoku Kogyo Kk | ケイ素を有する抗腫瘍性シクロヘキサンジアミン誘導体白金(iv)錯体 |
Non-Patent Citations (2)
Title |
---|
HAUGWITZ R. D.等: "[Bis(aminomethyl)dimethylsilane]platinum(II) dichloride: a potential antitumor agent", 《APPLIED ORGANOMETALLIC CHEMISTRY》 * |
WAYNE K. ANDERSON等: "Synthesis, Antitumor Activity, and Chemical Properties of Silaplatin and Related Platinum(II) and Platinum(IV) Complexes Derived from β-Silyl Amines", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114195830A (zh) * | 2021-11-30 | 2022-03-18 | 昆明贵研药业有限公司 | 一种顺式-氨-水-铂配合物的制备方法 |
CN114195830B (zh) * | 2021-11-30 | 2023-10-20 | 昆明贵研药业有限公司 | 一种顺式-氨-水-铂配合物的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5385274B2 (ja) | ホスファプラチン、ならびにシスプラチンおよびカルボプラチンに対し耐性を有する癌の治療におけるその使用 | |
CN109293702B (zh) | 一种四价铂多胺配合物、其制备方法及应用 | |
JPH0244838B2 (zh) | ||
Nagy et al. | Promising anticancer mono-and dinuclear ruthenium (III) dithiocarbamato complexes: systematic solution studies | |
CN102731580B (zh) | 一种双核铂(ii)-双膦酸类配合物及其制备方法和应用 | |
KR100239787B1 (ko) | 항종양 활성을 지니는 삼핵의 양이온성 백금 착물 및 이를 포함하는 약학적 조성물 | |
CN101899067A (zh) | 米铂的制备方法 | |
RU2140422C1 (ru) | Трехплатиновые комплексы pt(ii), способ их получения | |
US6413953B1 (en) | Pt(IV) antitumor agent | |
JP2749295B2 (ja) | 高分子白金錯化合物、その製造方法及びそれを有効成分とする抗ガン剤 | |
CN110423253A (zh) | 一种含单硅烷基的铂配合物及其应用 | |
EP0163316B1 (en) | Platinum-intercalative complexes for the treatment of cancer | |
Bergamini et al. | New PTA (1, 3, 5-triaza 7-phosphaadamantane) derivatives associating zwitterionic structure and coordinative ability | |
CN101768191A (zh) | 一种合成抗肿瘤药物Miriplatin的新方法 | |
Kozachkova et al. | Complexation of dichloro (ethylenediamine) palladium (II) with 1-hydroxyethylidene-1, 1-diphosphonic acid | |
CN108383880B (zh) | 靶向于卵巢癌耐药株的香豆素-铂(ii)配合物及其合成方法与应用 | |
Zou | Anti-Cancer N-Heterocyclic Carbene Complexes of Gold (III), Gold (I) and Platinum (II): Thiol “Switch-on” Fluorescent Probes, Thioredoxin Reductase Inhibitors and Endoplasmic Reticulum Targeting Agents | |
JPH02108693A (ja) | 白金(4)ジアミン錯体 | |
JPH10509159A (ja) | 抗腫瘍活性を有する三核性カチオン性プラチナ錯体、及びそれらを含有する医薬組成物 | |
CN106543234A (zh) | 以饱和链为桥的手性双核铂配合物及其制备方法和应用 | |
Yoo et al. | Synthesis of stable platinum complexes containing carborane in a carrier group for potential BNCT agents | |
CN113307829B (zh) | 一种以异羟肟酸衍生物为配体的铂(ii)配合物及其制备方法和应用 | |
CN102060878B (zh) | 顺式-碘、氯-((1r,2r)-1,2-环己二胺)合铂(ⅱ)的制备方法 | |
CN104230997B (zh) | 一种铂(ⅱ)配合物、其制备方法、药物组合物及应用 | |
CN102603812B (zh) | 一种双核铂(ⅱ)–唑来膦酸配合物及其制备和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200814 Address after: No. 801, yangyangyangxin courtyard, No. 158, Xiufeng West Road, Yiyang City, Hunan Province, 413000 Applicant after: Xiao Youlin Address before: 410000 No. 6112 Haipingyuan Production Plant No. 229 Guyuan Road, Changsha High-tech Development Zone, Hunan Province Applicant before: CHANGSHA ZEYIN BIOTECHNOLOGY Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20211207 Address after: 410000 601, No. 4, haipingyuan production plant, No. 229, Guyuan Road, high tech Development Zone, Changsha, Hunan Applicant after: Hunan keyin Biotechnology Co.,Ltd. Address before: 413000 room 801, yangguangxin courtyard, No. 158, Xiufeng West Road, Yiyang City, Hunan Province Applicant before: Xiao Youlin |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191108 |